Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine protects at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by stimulating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85 per cent protection when vaccinated 4 weeks before birth
• Antibodies from the mother transferred through placenta protect newborns from day one
• Protection possible with two-week gap before early delivery
• Vaccination during third trimester still provides meaningful infant protection

Persuasive evidence from the latest research

The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that half-year window, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scope of this study gives healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across varied populations and settings.

The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.

Methodology and scope of study

The research examined birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine works when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.

Grasping RSV and the threats

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.

The infection produces deep inflammation in the lungs and airways, making it dangerously difficult for affected infants to breathe and feed properly. Parents often witness their babies visibly struggling, their chests heaving as they try to pull sufficient oxygen into their compromised lungs. Whilst most infants get better with supportive care, a small but significant number die from respiratory syncytial virus complications yearly, making vaccination as prevention a critical public health imperative for defending the youngest and most vulnerable people in our communities.

• RSV triggers lung inflammation, causing severe breathing difficulties in infants
• Half of all infants contract the virus during their first few months alive
• Symptoms range from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK babies need serious hospital treatment for RSV each year
• Few babies succumb to RSV complications each year in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme began in 2024, health officials have stressed the significance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery offers approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.

The guidance from health authorities stays clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate differences across medical facilities, engagement approaches, and community involvement initiatives, though the national data shows robust and reliable protection regardless of geographical location.

• NHS trusts deploying diverse outreach initiatives to connect with pregnant women
• Regional disparities in vaccination coverage levels in different parts of England necessitate strategic intervention
• Regional health providers modifying schemes to meet community needs and circumstances

Practical implications and parent viewpoints

The vaccine’s outstanding effectiveness translates into real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the rollout of this safeguarding intervention, the 80% decrease in admissions equates to thousands of infants spared from serious illness. Parents no longer face the upsetting situation of watching their newborns struggle for breath or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has markedly changed the terrain of neonatal respiratory health, giving expectant mothers a preventative option to safeguard their youngest infants during those vital initial period.

For families like that of Malachi, whose serious RSV infection led to severe brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab highlights the life-altering consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women navigating their third trimester, converting what was once an inevitable seasonal threat into a manageable risk.